Labrys Biologics Secures $31,000,000 Series A Funding Round

  • Feed Type
  • Date
    1/4/2013
  • Company Name
    Labrys Biologics
  • Mailing Address
    1700 Owens Street San Francisco, CA 94158
  • Company Description
    Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine. Labrys’ lead candidate, RN-307, is an anti-CGRP monoclonal antibody for the treatment of chronic migraine slated to enter Phase 2 clinical trials in 2013.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $31,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Under the terms of the agreement with Pfizer, Labrys acquired worldwide rights to RN-307.
  • M&A Terms
  • Venture Investor
    venBio
  • Venture Investor
    Canaan Partners
  • Venture Investor
    InterWest Partners
  • Venture Investor
    Sofinnova Ventures

By posting a comment, you agree to our terms and conditions.